Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 52 pages report, published by Global Markets Direct

Keywords : Mycobacterium Tuberculosis Infections Therapeutic Products under Development, Key Players in Mycobacterium Tuberculosis Infections Therapeutics, Mycobacterium Tuberculosis Infections Pipeline Overview, Mycobacterium Tuberculosis Infections Pipeline, Mycobacterium Tuberculosis Infections Pipeline Assessment

Report ThumbnailSeptember-2013
Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mycobacterium Tuberculosis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycobacterium Tuberculosis Infections. Mycobacterium Tuberculosis Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mycobacterium Tuberculosis Infections.
- A review of the Mycobacterium Tuberculosis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mycobacterium Tuberculosis Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Mycobacterium Tuberculosis Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mycobacterium Tuberculosis Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Mycobacterium Tuberculosis Infections, H2 2013 8
  • Products under Development for Mycobacterium Tuberculosis Infections - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Products under Investigation by Universities/Institutes, H2 2013 11
  • Discovery and Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Combination Products, H2 2013 21
  • Assessment by Route of Administration, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Molecule Type, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 25
  • List of Tables
  • Number of Products Under Development for Mycobacterium Tuberculosis Infections, H2 2013 8
  • Products under Development for Mycobacterium Tuberculosis Infections - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 10
  • Number of Products under Investigation by Universities/Institutes, H2 2013 11
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Products under Investigation by Universities/Institutes, H2 2013 14
  • AstraZeneca PLC, H2 2013 15
  • GlaxoSmithKline plc, H2 2013 16
  • Affinium Pharmaceuticals, Inc., H2 2013 17
  • Oragenics, Inc., H2 2013 18
  • Ascenion GmbH, H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Combination Products, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 25
  • Mycobacterium Tuberculosis Infections Therapeutics - Drug Profile Updates 43
  • Mycobacterium Tuberculosis Infections Therapeutics - Dormant Products 45
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Mycobacterium Tuberculosis Infections Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Mycobacterium Tuberculosis Infections 8
  • Mycobacterium Tuberculosis Infections Therapeutics under Development by Companies 10
  • Mycobacterium Tuberculosis Infections Therapeutics under Investigation by Universities/Institutes 11
  • Discovery and Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Mycobacterium Tuberculosis Infections Therapeutics - Products under Development by Companies 13
  • Mycobacterium Tuberculosis Infections Therapeutics - Products under Investigation by Universities/Institutes 14
  • Companies Involved in Mycobacterium Tuberculosis Infections Therapeutics Development 15
  • AstraZeneca PLC 15
  • GlaxoSmithKline plc 16
  • Affinium Pharmaceuticals, Inc. 17
  • Oragenics, Inc. 18
  • Ascenion GmbH 19
  • Mycobacterium Tuberculosis Infections - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Combination Products 21
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • MU-1140 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • Fabl Inhibitor Program - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • MU-1140-S - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Aminopyrazinamides - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • Tetramic Acid Analogs - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • (BV-6481 + ethionamide) - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • MDR And XDR Tuberculosis Program - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • Thuggacines - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • Biotin Triazoles - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • Mycobacterial Gyrase Inhibitor Program - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • Riminophenazines - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • KKL-35 - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • R-12 - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • R-13 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • rAMtb-SIVgag Vaccine - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • Mycobacterium Tuberculosis Infections Therapeutics - Drug Profile Updates 43
  • Mycobacterium Tuberculosis Infections Therapeutics - Dormant Products 45
  • Mycobacterium Tuberculosis Infections - Product Development Milestones 46
  • Featured News & Press Releases 46
  • Aug 01, 2013: Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infections with Pulmaquin and Lipoquin 46
  • Jun 17, 2013: Researchers Identify New Compound Effective Against Persistent And Drug-Resistant Tuberculosis 47
  • Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 49
  • Dec 01, 2011: Vaccine Targeting Latent Tuberculosis Enters Clinical Testing 49
  • Appendix 51
  • Methodology 51
  • Coverage 51
  • Secondary Research 51
  • Primary Research 51
  • Expert Panel Validation 51
  • Contact Us 52
  • Disclaimer 52

Please select a license type

Share

Related Products

Global Markets DirectMycobacterium Tuberculosis Infections - Pipeline Review, H2 2013Product ThumbnailMycobacterium Tuberculosis Infections - Pipeline Review, H2 2013, Industry ReportProduct #: 113345
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved